title: Therapy: Lenvatinib and radioiodine-refractory thyroid cancers.
authors.affiliation: Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
authors.forename: Lara
authors.initials: L
authors.lastname: Dunn
authors.affiliation: Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
authors.forename: James A
authors.initials: JA
authors.lastname: Fagin
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011804:Quinolines / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000188:drug therapy*
chemical_list: D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011804:Quinolines
references.citation: Curr Opin Cell Biol. 2009 Apr;21(2):296-303
references.pmid: 19231149
references.citation: Cancer Res. 2004 Oct 1;64(19):7099-109
references.pmid: 15466206
references.citation: Int J Cancer. 2008 Feb 1;122(3):664-71
references.pmid: 17943726
references.citation: Clin Cancer Res. 2008 Sep 1;14(17):5459-65
references.pmid: 18765537
references.citation: N Engl J Med. 2015 Feb 12;372(7):621-30
references.pmid: 25671254
references.citation: J Clin Oncol. 2013 Jun 10;31(17):2205-18
references.pmid: 23669226
references.citation: Lancet. 2014 Jul 26;384(9940):319-28
references.pmid: 24768112
references.citation: Cancer Cell. 2014 Nov 10;26(5):605-22
references.pmid: 25517747